Migraine readout completes December hat trick for surging Axsome

Axsome’s winning streak continued as its third auspicious clinical readout this month augurs a planned 2H20 NDA submission that could allow the company to carve out a niche for AXS-07 in acute migraine.

Axsome Therapeutics Inc. (NASDAQ:AXSM) said Monday that its meloxicam/rizatriptan combination significantly beat placebo on the co-primary endpoints of the Phase III MOMENTUM trial, while also showing superiority to each of its components in the study’s active comparator arms. MOMENTUM studied AXS-07 in acute migraine patients with a history of inadequate response to current treatments...